<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine</title>
	<atom:link href="http://www.rxtimes.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Sun, 20 May 2012 01:00:46 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-56/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-56/#comments</comments>
		<pubDate>Sun, 20 May 2012 01:00:46 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-56/</guid>
		<description><![CDATA[PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg) SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-56/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-55/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-55/#comments</comments>
		<pubDate>Sat, 19 May 2012 01:00:13 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-55/</guid>
		<description><![CDATA[Taro to Announce Financial Results for the Quarter Ended March 31, 2012 HAWTHORNE, N.Y.&#8211;(BUSINESS WIRE)&#8211;Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”), announced today that it will release its financial results for the quarter ended March 31, 2012 after market close on Thursday, May 24, 2012. Additionally, the release will be accessible on Taro’s website at [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-55/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-54/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-54/#comments</comments>
		<pubDate>Fri, 18 May 2012 01:00:26 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-54/</guid>
		<description><![CDATA[Emergent BioSolutions Receives FDA Approval for BioThrax Administered Intramuscularly in a Three-Dose Primary Series Followed by Booster Doses ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211;Emergent BioSolutions Inc. (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) to change the administration schedule of BioThrax® (Anthrax Vaccine Adsorbed) to a [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-54/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-53/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-53/#comments</comments>
		<pubDate>Thu, 17 May 2012 01:00:52 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-53/</guid>
		<description><![CDATA[Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting SEATTLE&#8211;(BUSINESS WIRE)&#8211;May 16, 2012&#8211;Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5, 2012 in Chicago, Illinois. “Overall Survival (OS) Benefit with [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-53/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-52/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-52/#comments</comments>
		<pubDate>Wed, 16 May 2012 01:00:59 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-52/</guid>
		<description><![CDATA[Covidien Completes Acquisition of superDimension, Ltd. DUBLIN&#8211;(BUSINESS WIRE)&#8211;Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of superDimension, Ltd., for an aggregate consideration of approximately $300 million, with future earn out payments possible. Pursuant to the terms of the acquisition agreement, Covidien has acquired [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-52/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-51/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-51/#comments</comments>
		<pubDate>Tue, 15 May 2012 01:00:07 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-51/</guid>
		<description><![CDATA[Partnering Bootcamp Kicks Off ChinaBio® Partnering Forum 2012 in Suzhou CARLSBAD, Calif. &#38; SUZHOU, China&#8211;(BUSINESS WIRE)&#8211;ChinaBio® Partnering Forum 2012 will be held at the Kempinski Hotel Suzhou May 23–24 in Suzhou, China with a special Partnering Bootcamp &#8211; a half-day pre-conference program &#8211; held May 22. Array BioPharma and Genentech&#8217;s Strategic Alliance Voted Breakthrough Alliance [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-51/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-50/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-50/#comments</comments>
		<pubDate>Sat, 12 May 2012 01:00:09 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-50/</guid>
		<description><![CDATA[Vascular Expert Supports FDA Warning about Experimental Therapy for MS Patients MIAMI&#8211;(BUSINESS WIRE)&#8211;Vascular expert Barry Katzen, M.D., pushes for new clinical trials to confirm experimental hi-risk therapy benefits multiple sclerosis patients. Galectin Therapeutics Reports First Quarter 2012 Financial Results NEWTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Galectin Therapeutics announces first quarter 2011 results. FDA Advisory Committee Supports Approval of Gilead’s [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-50/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-49/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-49/#comments</comments>
		<pubDate>Fri, 11 May 2012 01:00:10 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-49/</guid>
		<description><![CDATA[FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada® (emtricitabine and tenofovir disoproxil fumarate) to reduce the [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-49/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-49/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-49/#comments</comments>
		<pubDate>Fri, 11 May 2012 01:00:10 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-49/</guid>
		<description><![CDATA[FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada® (emtricitabine and tenofovir disoproxil fumarate) to reduce the [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-49/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacy News</title>
		<link>http://www.rxtimes.com/pharmacy-news-48/</link>
		<comments>http://www.rxtimes.com/pharmacy-news-48/#comments</comments>
		<pubDate>Wed, 09 May 2012 01:00:17 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/pharmacy-news-48/</guid>
		<description><![CDATA[McKesson Corporation to Present at the Bank of America Merrill Lynch Health Care Conference SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;McKesson Corporation (NYSE:MCK) today announced that Jeff Campbell, executive vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas at 1:40 p.m. PT on Tuesday, May 15, 2012. [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pharmacy-news-48/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

